




1634

PATENT

Attorney Docket No.: 29345/36972A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kamb et al.)	I hereby certify that this paper is being
Application Serial No.: 09/990,912 ✓)	deposited with the United States Postal
Filed: November 16, 2001)	Service with sufficient postage as first
For: Beta-Catenin Assays and)	class mail, postage prepaid, in an
Compositions Therefrom)	envelope addressed to: Commissioner for
Group Art Unit: 1634 ✓)	Patents, P.O. Box 1450, Alexandria, VA
Examiner: Jeffrey Norman Fredman)	22313-1450 on this date:
)	June 26, 2003
)	
)	Lynn L. Janulis
)	Reg. No. 53,066
)	Agent for Applicants

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97, AND 1.98**

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the applicants call to the attention of the Examiner the enclosed publications, A1-A2, B1-B2, and C19-C23 as listed on the attached Form PTO/SB/08A, which may be considered material to the examination of the above-identified patent application. Eighteen "C type" references were submitted previously in an information disclosure statement and Form PTO-1449, but these documents were not numbered.


In accordance with 37 C.F.R. § 1.97(e), each document contained in the information disclosure statement was first cited in the International Search Report from the European Patent Office (International Search Authority) in a counterpart PCT application (PCT/US01/43755) less than three months prior to filing of this supplemental information disclosure statement (IDS).

No fee is required for submission of this statement because each new item of information was first cited in a counterpart PCT International Application and no item of information was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this statement. However, should the Patent Office determine that a fee is due for consideration of this supplemental information disclosure statement and accompanying publications, the Patent Office is hereby authorized to charge said fee to Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

By:


Lynn L. Janulis
Reg. No. 53,066

June 26, 2003



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/990,912
				Filing Date	November 16, 2001
				First Named Inventor	Carl Alexander Kamb
				Art Unit	1645
				Examiner Name	Jeffrey Norman Fredman
Sheet	1	of	1	Attorney Docket Number	29345/36972A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	5,646,250	07-08-1997	Doheny Eye Institute	
	A2	5,955,275	09-21-1999	Arcaris, Inc.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	B1	WO 00/63246	10-26-2000	Adherex Technologies Inc.	
	B2	WO 00/64933	11-02-2000	Kyowa Hakko Kogyo Co., Ltd.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	C19	HE et al., "Identification of c-MYC as a Target of the APC Pathway," Science 281:1509-512 (1998)
	C20	HÜLSKEN et al., "E-Cadherin and APC Compete for the Interaction with β -Catenin and the Cytoskeleton," The Journal of Cell Biology 127:2061-2069 (1994)
	C21	NOVAK et al., "Signaling through β -catenin and Lef/Tcf," Cell. Mol. Life Sci. 56: 523-537 (1999)
	C22	SPARKS et al, "Mutational Analysis of the APC/ β -Catenin/Tcf Pathway in Colorectal Cancer," 58: 1130-1134 (1998)
	C23	International Search Report, PCT/US01/43755, European Patent Office.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.